Auckland Cancer Society Research Centre

Targeting hypoxia: Oxygen mimetic radiosensitisers

Targeting hypoxia oxygen mimetic radiosensitisers

Nitroimidazole radiosensitisers have been the subject of investigation for several decades with only one agent being used clinically. Technical advances in radiotherapy techniques have resulted in new therapies such as stereotactic body radiotherapy (SBRT). These new approaches have provided new opportunities for the use of radiosensitisers.  We are exploring the development of novel nitroimidazole compounds whose radical and physicochemical properties have been optimised for use in conjunction with SBRT in collaboration with Dr Kevin Hicks, Dr Frederik Pruijn, Dr Stephen Jamieson and Professor Bill Wilson from the Experimental Therapeutics Group.


Financial support from Cancer Society NZ, Australian Institute of Nuclear Science and Engineering, The University of Auckland Faculty Research Development Fund, The University of Auckland Biopharma Thematic Research Initiative, and UniServices Ltd is gratefully acknowledged.


Related publications

Bonnet M, Hong C, Gu Y, Anderson RF, Wilson WR, Pruijn FB, Wang J, Hicks KO, Hay, M.P. Novel nitroimidazole alkylsulfonamides as hypoxic cell radiosensitisers. Bioorg. Med. Chem. 22, 2123-2132, 2014. (PMID: 24650701)

Hay MP, Hicks KO, Wang J. Hypoxia directed drug strategies to target the tumor microenvironment. In Tumor Microenvironment and Cellular Stress. Signaling, Metabolism, Imaging, and Therapeutic Targets. Series: Advances in Experimental Medicine and Biology, Vol. 772. Koumenis, C., Hammond, E., Giaccia, A. (Eds.) 2014, Nov 29, p111-145. ISBN 978-1-4614-5914-9. (PMID: 23740105)